RKIP inhibits gastric cancer cell survival and invasion by regulating the expression of HMGA2 and OPN

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11949-11958

  Liu, Hongyi ^a   Li, Peng ^a   Li, Bing ^a   Sun, Peng ^a   Zhang, Jiajin ^a   Wang, Baishi ^a   Jia, Baoqing ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; Gastric cancer; HMGA2; Proliferation; RKIP

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA; OSTEOPONTIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL INVASION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; NONVIRAL GENE THERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT PLASMID; RNA INTERFERENCE; STOMACH CANCER; WESTERN BLOTTING; CELL CULTURE; CELL PROLIFERATION; GENETICS; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; OSTEOPONTIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; STOMACH NEOPLASMS;

EID: 84925283559     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2486-8     Document Type: Article

References (45)

1. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al. Suppression of raf-1 kinase activity and map kinase signalling by rkip. Nature. 1999;401:173–7.
2. Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (rkip): a physiological regulator and future therapeutic target. Expert Opin Ther Targets. 2008;12:1275–87.
3. Lu TP, Tsai MH, Hsiao CK, Lai LC, Chuang EY. Expression and functions of semaphorins in cancer. Transl Cancer Res. 2012;1:74–87.
4. Khamis ZI, Iczkowski KA, Sang QX. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. Med Res Rev. 2012;32:1026–77.
5. Yamada Y. Molecular therapy for gastric cancer. Chin Clin Oncol. 2013;2:5.
6. Wang YX, Wang DW, Zhu XM, Zhao F, Leung KC. Carbon coated superparamagnetic iron oxide nanoparticles for sentinel lymph nodes mapping. Quant Imaging Med Surg. 2012;2:53–6.
7. Kang B, Sun XH. Regulation of cancer stem cells by RING finger ubiquitin ligases. Stem Cell Investig. 2014;1:5.
8. Smith HS, Smith JM, Smith AR. An overview of nausea/vomiting in palliative medicine. Ann Palliat Med. 2012;1:103–14.
9. Fedele M, Palmieri D, Fusco A. Hmga2: a pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol. 2010;326:19–24.
10. Wu J, Wei JJ. Hmga2 and high-grade serous ovarian carcinoma. J Mol Med. 2013;91:1155–65.
11. Cleynen I, Van de Ven WJ. The hmga proteins: a myriad of functions (review). Int J Oncol. 2008;32:289–305.
12. Young AR, Narita M. Oncogenic hmga2: short or small? Genes Dev. 2007;21:1005–9.
13. Jonson L, Christiansen J, Hansen TV, Vikesa J, Yamamoto Y, Nielsen FC. Imp3 rnp safe houses prevent mirna-directed hmga2 mrna decay in cancer and development. Cell Rep. 2014;7:539–51.
14. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. Hmga2 maintains oncogenic ras-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol. 2009;174:854–68.
15. Pagel CN, Wasgewatte Wijesinghe DK, Taghavi Esfandouni N, Mackie EJ. Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle. J Cell Commun Signal. 2013.
16. Nagoshi S. Osteopontin: versatile modulator of liver diseases. Hepatol Res Off J Jpn Soc Hepatol. 2014;44:22–30.
17. Gimba ER, Tilli TM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013;331:11–7.
18. Cheng C, Gao S, Lei G. Association of osteopontin with osteoarthritis. Rheumatol Int. 2014.
19. Chien CY, Tsai HT, Su LJ, Chuang HC, Shiu LY, Huang CC, et al. Aurora-a signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior. Oncotarget. 2014;5:2243–62.
20. Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int. 2013;93:348–54.
21. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003;95:878–89.
22. Xu YF, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, et al. Pebp1 downregulation is associated to poor prognosis in hcc related to hepatitis b infection. J Hepatol. 2010;53:872–9.
23. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The role of b-raf mutations in melanoma and the induction of emt via dysregulation of the nf-kappab/snail/rkip/pten circuit. Genes Cancer. 2010;1:409–20.
24. Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, et al. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol. 2008;61:524–9.
25. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 2009;7:832–40.
26. Minn AJ, Bevilacqua E, Yun J, Rosner MR. Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle. 2012;11:2452–7.
27. Bonavida B, Baritaki S. The novel role of yin yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated nf-kappab/snail/yy1/rkip/pten circuitry. Crit Rev Oncog. 2011;16:211–26.
28. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.
29. Wu Z, Fu C, Shi L, Ruan L, Lin D, Guo C. Structural basis for rkip binding with its substrate raf1 kinase. Biotechnol Lett. 2014;36:1869–74.
30. Bu Z, Zheng Z, Zhang L, Li Z, Sun Y, Dong B, et al. LGR5 is a promising biomarker for patients with stage I and II gastric cancer. Chin J Cancer Res. 2013;25:79–89.
31. McDaniel K, Correa R, Zhou T, Johnson C, Francis H, Glaser S, et al. Functional role of microvesicles in gastrointestinal malignancies. Ann Transl Med. 2013;1:4.
32. Franceschi F, Zuccala G, Roccarina D, Gasbarrini A. Clinical effects of helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol. 2014;11:234–42.
33. Bu Z, Ji J. A current view of gastric cancer in China. Transl Gastrointest Cancer. 2013;2(S1):1–4.
34. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011;137:1151–73.
35. Merchionne F, Iacopino P, Minoia C, Iacobazzi A, Rana A, Serratl S, et al. Targeted strategies in the treatment of primary gastric lymphomas: from rituximab to recent insights into potential new drugs. Curr Med Chem. 2014;21:1005–16.
36. Hardbower DM, Peek Jr RM, Wilson KT. At the bench: helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol. 2014;96:201–12.
37. Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 1846;2014:232–7.
38. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. Rkip: much more than raf kinase inhibitory protein. J Cell Physiol. 2013;228:1688–702.
39. Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (rkip) in cancer. Cancer Metastasis Rev. 2012;31:615–20.
40. Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding J, et al. Microrna-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting hmga2. Int J Oncol. 2014;44:2050–8.
41. Xi YN, Xin XY, Ye HM. Effects of hmga2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells. Asian Pac J Trop Med. 2014;7:289–92.
42. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving lin28 and let-7. EMBO J. 2009;28:347–58.
43. Wei J, Li H, Wang S, Li T, Fan J, Liang X, et al. Let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating hmga2. Stem Cells Dev. 2014;23:1452–63.
44. Chen KJ, Hou Y, Wang K, Li J, Xia Y, Yang XY, et al. Reexpression of let-7 g microrna inhibits the proliferation and migration via k-ras/hmga2/snail axis in hepatocellular carcinoma. BioMed Res Int. 2014;2014:742417.
45. Sun M, Gomes S, Chen P, Frankenberger CA, Sankarasharma D, Chung CH, et al. Rkip and hmga2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene. 2013;33:3528–37.